{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:35:20Z","timestamp":1789871720553,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CSPC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12\u2009months after the first-line platinum-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open-label, single-arm and multicenter clinical trial. The ORR was the interim primary objective, and the DCR, AEs and QOL were the secondary objectives. The impact of factors on efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Totally, 115 patients were enrolled in this study and included in the ITT population. Moreover, 101 patients were included in the safety population. The median follow-up time was 4\u2009months (IQR 2\u20136). In the ITT population, the confirmed ORR was 37.4% (95% CI, 28.4\u201346.4%), and the DCR was 65.2% (95% CI, 56.4\u201374.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were significantly correlated with the ORR. The ORR was significantly higher in patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients who experience platinum-resistant and platinum-refractory relapse, the use of PLD may be acceptable because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a low CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for satisfactory efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-020-00736-2","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T20:04:20Z","timestamp":1610309060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Zhen","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanguang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"736_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"736_CR2","unstructured":"Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2014\/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017."},{"key":"736_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1758834014544121","volume":"6","author":"D Luvero","year":"2014","unstructured":"Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6:229\u201339.","journal-title":"Ther Adv Med Oncol"},{"key":"736_CR4","doi-asserted-by":"crossref","unstructured":"Ushijima K. (2010) Treatment for Recurrent Ovarian Cancer - At First Relapse Journal of Oncology 2010.","DOI":"10.1155\/2010\/497429"},{"key":"736_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ray CM, Spira AI, et al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017;34:103.","journal-title":"Med Oncol"},{"key":"736_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/IGC.0000000000001222","volume":"28","author":"R Parikh","year":"2018","unstructured":"Parikh R, Kurosky SK, Udall M, et al. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian Cancer: a retrospective medical record Review. Int J Gynecol Cancer. 2018;28:738\u201348.","journal-title":"Int J Gynecol Cancer"},{"key":"736_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La BNM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat. 2016;29:90\u2013106.","journal-title":"Drug Resist Updat"},{"key":"736_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","volume":"4","author":"MA Bookman","year":"1999","unstructured":"Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87\u201394.","journal-title":"Oncologist"},{"key":"736_CR9","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","volume":"35","author":"P Sandro","year":"2017","unstructured":"Sandro P, Giovanni S, Alessandra B, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian Cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017;35:3347\u201353.","journal-title":"J Clin Oncol"},{"key":"736_CR10","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1002\/cncr.30830","volume":"123","author":"F Tomao","year":"2017","unstructured":"Tomao F, D'Incalci M, Biagioli E, et al. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality? Cancer. 2017;123:3450\u20139.","journal-title":"Cancer"},{"key":"736_CR11","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e116","volume":"30","author":"R Zang","year":"2019","unstructured":"Zang R, Zhu J. Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer? J Gynecol Oncol. 2019;30:e116.","journal-title":"J Gynecol Oncol"},{"key":"736_CR12","doi-asserted-by":"crossref","unstructured":"Bergamini A, Bocciolone L, Fodor A et al. (2019) Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. Int J Gynecol Cancer 0:1\u20136.","DOI":"10.1136\/ijgc-2019-000624"},{"key":"736_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GF Rustin","year":"2004","unstructured":"Rustin GF, Quinn MF, Thigpen TF, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96:487\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"736_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SF, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"736_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1\u201310.","journal-title":"Control Clin Trials"},{"key":"736_CR16","doi-asserted-by":"crossref","unstructured":"Banerjee SN, Oza AM, Birrer MJ, et al. A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC). J Clin Oncol. 2016;34.","DOI":"10.1200\/JCO.2016.34.15_suppl.5569"},{"key":"736_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ygyno.2015.06.025","volume":"138","author":"J Erriquez","year":"2015","unstructured":"Erriquez J, Becco P, Olivero M, et al. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015;138:627\u201333.","journal-title":"Gynecol Oncol"},{"key":"736_CR18","first-page":"1505","volume":"27","author":"E Ghisoni","year":"2017","unstructured":"Ghisoni E, Maggiorotto F, Mittica G, et al. TOP2A over-expression as marker of response to pegylatedlyposomal doxorubicin (PLD) in epithelial ovarian cancers. Int J Gynecol Cancer. 2017;27:1505.","journal-title":"Int J Gynecol Cancer"},{"key":"736_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1008240421028","volume":"8","author":"EA Eisenhauer","year":"1997","unstructured":"Eisenhauer EA, Vermorken JB, Van GM, Fau VOAT. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol. 1997;8:963\u20138.","journal-title":"Ann Oncol"},{"key":"736_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00280-019-03834-1","volume":"84","author":"KM Kobayashi","year":"2019","unstructured":"Kobayashi KM, Yunokawa M, Bun S, et al. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer. Cancer Chemother Pharmacol. 2019;84:33\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"736_CR21","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Cecere SC, Du BA, et al. Treatment of recurrent ovarian cancer. Annals of Oncol. 2017;28:viii51\u20136.","journal-title":"Annals of Oncol"},{"key":"736_CR22","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/jnci\/djr282","volume":"103","author":"CK Lee","year":"2011","unstructured":"Lee CK, Friedlander M, Brown C, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011;103:1338\u201342.","journal-title":"J Natl Cancer Inst"},{"key":"736_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/IGC.0b013e3181a1c7aa","volume":"19","author":"JS Tanguay","year":"2009","unstructured":"Tanguay JS, Ansari J, Buckley L, Fernando I. Epithelial ovarian cancer: role of pegylated liposomal doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer. 2009;19:361\u20136.","journal-title":"Int J Gynecol Cancer"},{"key":"736_CR24","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/cncr.23374","volume":"112","author":"NS Azad","year":"2008","unstructured":"Azad NS, Annunziata CM, Steinberg SM, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008;112:1726\u201332.","journal-title":"Cancer"},{"key":"736_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ygyno.2005.10.027","volume":"101","author":"HH Chou","year":"2006","unstructured":"Chou HH, Wang KL, Chen CA, et al. Pegylated liposomal doxorubicin (Lipo-Dox\u00ae) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol. 2006;101:423\u20138..","journal-title":"Gynecol Oncol"},{"key":"736_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/CMAR.S15558","volume":"3","author":"M Markman","year":"2011","unstructured":"Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res. 2011;3:219\u201325.","journal-title":"Cancer Manag Res"},{"key":"736_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","volume":"12","author":"RL Coleman","year":"2007","unstructured":"Coleman RL, Gordon A, Barter J, et al. Early changes in CA125 after treatment with Pegylated liposomal doxorubicin or Topotecan do not always reflect best response in recurrent ovarian Cancer patients. Oncologist. 2007;12:72\u20138.","journal-title":"Oncologist"},{"key":"736_CR28","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","volume":"15","author":"BHW Ten","year":"1997","unstructured":"Ten BHW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183\u201393.","journal-title":"J Clin Oncol"},{"key":"736_CR29","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811\u20138.","journal-title":"J Clin Oncol"},{"key":"736_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"26","author":"F Gabriella","year":"2008","unstructured":"Gabriella F, Manuela L, Domenica L, et al. Phase III trial of gemcitabine compared with Pegylated liposomal doxorubicin in progressive or recurrent ovarian Cancer. J Clin Oncol. 2008;26:890\u20136.","journal-title":"J Clin Oncol"},{"key":"736_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 1998;16:405\u201310.","journal-title":"J Clin Oncol"},{"key":"736_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003;88:130\u20135.","journal-title":"Gynecol Oncol"},{"key":"736_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","volume":"16","author":"S Pignata","year":"2015","unstructured":"Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16:561\u20138.","journal-title":"Lancet Oncol"},{"key":"736_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/annonc\/mdh025","volume":"15","author":"BHWM Ten","year":"2004","unstructured":"Ten BHWM, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004;15:100\u20133.","journal-title":"Ann Oncol"},{"key":"736_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ygyno.2004.03.047","volume":"94","author":"NS Horowitz","year":"2004","unstructured":"Horowitz NS, Hua J, Gibb RK, et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004;94:67\u201373.","journal-title":"Gynecol Oncol"},{"key":"736_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601\u20139.","journal-title":"Oncologist"},{"key":"736_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141.","journal-title":"J Clin Oncol"},{"key":"736_CR38","unstructured":"NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2019. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer.pdf. Accessed September 17, 2019.."},{"key":"736_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","volume":"24","author":"KM Zanotti","year":"2001","unstructured":"Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001;24:767\u201379.","journal-title":"Drug Saf"},{"key":"736_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/annonc\/mdq352","volume":"22","author":"A Poveda","year":"2011","unstructured":"Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22:39\u201348.","journal-title":"Ann Oncol"},{"key":"736_CR41","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs. 2011;71:2531\u201358.","journal-title":"Drugs"},{"key":"736_CR43","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","volume":"15","author":"V Nikolaou","year":"2016","unstructured":"Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15:1625\u201333.","journal-title":"Expert Opin Drug Saf"},{"key":"736_CR42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.biopha.2017.09.059","volume":"95","author":"A Shafei","year":"2017","unstructured":"Shafei A, El BW, Sobhy A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209\u201318.","journal-title":"Biomed Pharmacother"},{"key":"736_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440\u20139.","journal-title":"Ann Oncol"},{"key":"736_CR45","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus Pegylated liposomal doxorubicin in recurrent ovarian Cancer. J Clin Oncol. 2010;28:3107\u201314.","journal-title":"J Clin Oncol"},{"key":"736_CR46","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","volume":"19","author":"CY Lan","year":"2018","unstructured":"Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19:1239\u201346.","journal-title":"Lancet Oncol"},{"key":"736_CR47","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1097\/IGC.0000000000001125","volume":"27","author":"C Omichi","year":"2017","unstructured":"Omichi C, Nakamura K, Haraga J, et al. The influence of adverse effects on quality of life of survivors of gynecologic Cancer. Int J Gynecol Cancer. 2017;27:2014\u20139.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-020-00736-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T20:14:09Z","timestamp":1610309649000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00736-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["736"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00736-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38992\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38992\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38992\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was registered in the Chinese Clinical Trial Registry under the number is ChiCTR1900022962. Registered 2019-05-05 - Retrospectively registered. All procedures performed in studies involving human participants were in accordance with ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}